Insitro

Insitro is a drug discovery and development company that uses machine learning and data to identify and develop new medicines. The company's platform integrates in vitro cellular data produced in its labs with human clinical data to help redefine disease. Insitro's pipeline includes wholly-owned and partnered therapeutic programs in metabolism, oncology, and neuroscience.

Recursion is a techbio company that uses artificial intelligence to accelerate drug discovery. The company's platform combines hardware, software, and data to create a more efficient and effective drug discovery process. Recursion has a broad pipeline of drug candidates in development, and it has partnered with several leading pharmaceutical companies. The company is headquartered in Salt Lake City, Utah.

Atomwise is an artificial intelligence (AI)-driven drug discovery company that uses machine learning to discover and develop new small molecule medicines. The company's AI engine combines the power of convolutional neural networks with massive chemical libraries to identify new drug candidates. Atomwise has a wholly owned pipeline of drug discovery programs and also partners with other pharmaceutical companies to co-develop drugs. The company's investors include prominent venture capital firms and pharmaceutical companies.

Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.

Valo is a company that uses AI-driven technology to transform the discovery and development of life-changing medicines. They combine machine learning, tissue biology, and patient data to create a suite of powerful capabilities that bring the future of drug discovery and development to bear. Valo's team of software engineers, data scientists, biologists, medicinal chemists, and big-picture thinkers are dedicated to advancing the combined power of technology and patient data.

AiCure provides a patient-centric eClinical trial management platform that enhances drug development through improved medication adherence rates, more powerful analysis and prediction of treatment response using digital biomarkers, and reduced clinical tech burden. AiCure's solutions support traditional, decentralized, or hybrid trials and offer flexibility to meet the needs of various research designs.

DrugCard is an AI-enabled Data Intelligence platform designed to streamline drug safety routines, particularly in pharmacovigilance. It offers solutions for local literature screening, catering to CROs, MAHs, and freelancers in the pharmaceutical industry. The platform supports multiple languages, covers various medical journals, and saves significant time compared to manual approaches. DrugCard aims to enhance pharmacovigilance processes by leveraging AI, automation, and traceability to meet regulatory requirements and improve screening results.

Beacon Biosignals provides an EEG neurobiomarker platform that is designed to accelerate clinical trials and enable new treatments for patients with neurological and psychiatric diseases. Their platform is powered by machine learning and a world-class clinico-EEG database, which allows them to analyze existing EEG data for insights into mechanisms, PK/PD, and patient stratification. This information can be used to guide further development efforts, optimize clinical trials, and enhance understanding of treatment efficacy.

Variational AI is a company that uses generative AI to discover novel drug-like small molecules with optimized properties for defined targets. Their platform, Enki™, is the first commercially accessible foundation model for small molecules. It is designed to make generating novel molecule structures easy, with no data required. Users simply define their target product profile (TPP) and Enki does the rest. Enki is an ensemble of generative algorithms trained on decades worth of experimental data with proven results. The company was founded in September 2019 and is based in Vancouver, BC, Canada.

Iambic Therapeutics is a cutting-edge AI-driven drug discovery platform that tackles the most challenging design problems in drug discovery, addressing unmet patient need. Its physics-based AI algorithms drive a high-throughput experimental platform, converting new molecular designs to new biological insights each week. Iambic's platform optimizes target product profiles, exploring multiple profiles in parallel to ensure that molecules are designed to solve the right problems in disease biology. It also optimizes drug candidates, deeply exploring chemical space to reveal novel mechanisms of action and deliver diverse high-quality leads.

Oncora Medical is a healthcare technology company that provides software and data solutions to oncologists and cancer centers. Their products are designed to improve patient care, reduce clinician burnout, and accelerate clinical discoveries. Oncora's flagship product, Oncora Patient Care, is a modern, intelligent user interface for oncologists that simplifies workflow, reduces documentation burden, and optimizes treatment decision making. Oncora Analytics is an adaptive visual and backend software platform for regulatory-grade real world data analytics. Oncora Registry is a platform to capture and report quality data, treatment data, and outcomes data in the oncology space.

SOMA is a Research Automation Platform that accelerates medical innovation by providing up to 100x speedup through process automation. The platform collates and analyzes medical research articles, extracting important concepts and identifying causal and associative relationships between them. It organizes this information into a specialized database forming a knowledge graph. Researchers can retrieve causal chains, access specific research articles, and build pipelines for tasks like article search, concept analysis, drug repurposing, and target discovery. SOMA enhances literature review by finding relevant articles based on causal chains and keywords, enabling users to uncover hidden connections efficiently. The platform is freemium, offering basic functionality for free with the option to subscribe for advanced features.

Intelligencia AI is a leading provider of AI-powered solutions for the pharmaceutical industry. Our suite of solutions helps de-risk and enhance clinical development and decision-making. We use a combination of data, AI, and machine learning to provide insights into the probability of success for drugs across multiple therapeutic areas. Our solutions are used by many of the top global pharmaceutical companies to improve their R&D productivity and make more informed decisions.

Modality.AI is an AI application that has developed an automated, clinically validated system to assess neurological and psychiatric states both in clinic and remotely. The platform utilizes conversational AI to monitor conditions accurately and consistently, allowing researchers and clinicians to review data in near real-time and monitor treatment response over time. Modality.AI collaborates with world-class AI/Machine Learning experts and leading institutions to provide a HIPAA-compliant system for assessing various indications such as ALS, Parkinson's, depression, autism, Huntington's Disease, schizophrenia, and mild cognitive impairment. The platform enables convenient monitoring at home through streaming and analysis of speech and facial responses, without the need for special software or apps. Modality.AI is accessible on various devices with a browser, webcam, and microphone, offering a new approach to efficient and cost-effective clinical trials.

fxis.ai is an AI company that specializes in developing cutting-edge artificial intelligence tools and applications. With a focus on innovation and technology, fxis.ai aims to provide advanced solutions to various industries, including healthcare, finance, and marketing. The company's expertise lies in machine learning, natural language processing, and computer vision, enabling them to create intelligent systems that can automate tasks, analyze data, and improve decision-making processes. By leveraging the power of AI, fxis.ai helps businesses enhance efficiency, productivity, and competitiveness in today's digital age.

NeuProScan is an AI platform designed for the early detection of pre-clinical Alzheimer's from MRI scans. It utilizes AI technology to predict the likelihood of developing Alzheimer's years in advance, helping doctors improve diagnosis accuracy and optimize the use of costly PET scans. The platform is fully customizable, user-friendly, and can be run on devices or in the cloud. NeuProScan aims to provide patients and healthcare systems with valuable insights for better planning and decision-making.

Genesis Therapeutics is a cutting-edge platform that leverages molecular AI technology to discover and develop innovative medicines with exceptional potency and selectivity. The platform, known as GEMS (Generative AI for Drug Discovery), combines AI and physics research to identify drug candidates against challenging targets at an accelerated pace. The company's approach involves designing highly potent and selective drugs for chemically complex targets, driven by a team of collaborative minds across AI and biotech disciplines. Genesis Therapeutics is dedicated to advancing breakthrough medicines and bringing new hope to patients through its unique blend of technology and expertise.

Synthace is a software and expertise platform designed for Discovery Biology Teams to streamline and optimize their experiments in assay development, media optimization, and purification process development. The platform offers software solutions, training, and on-site support from specialists to help scientists conduct experiments more efficiently and effectively. By leveraging multifactorial methods and automation, Synthace aims to accelerate drug discovery processes and deliver faster, definitive results.

Insitro is a drug discovery and development company that uses machine learning and data to identify and develop new medicines. The company's platform integrates in vitro cellular data produced in its labs with human clinical data to help redefine disease. Insitro's pipeline includes wholly-owned and partnered therapeutic programs in metabolism, oncology, and neuroscience.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques. The company's proprietary AI platform is used to identify, re-innovate, and develop potential new therapies. BioXcel Therapeutics has a pipeline of product candidates in various stages of development, including BXCL501 for agitation in dementia, BXCL701 for cocaine use disorder, and BXCL801 for acute suicidal ideation and behavior in patients with major depressive disorder.

Recursion is a techbio company that uses artificial intelligence to accelerate drug discovery. The company's platform combines hardware, software, and data to create a more efficient and effective drug discovery process. Recursion has a broad pipeline of drug candidates in development, and it has partnered with several leading pharmaceutical companies. The company is headquartered in Salt Lake City, Utah.

Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.

JADBio is an automated machine learning (AutoML) platform designed to accelerate biomarker discovery and drug development processes. It offers a no-code solution that automates the discovery of biomarkers and interprets their role based on research needs. JADBio can parse multi-omics data, including genomics, transcriptome, metagenome, proteome, metabolome, phenotype/clinical data, and images, enabling users to efficiently discover insights for various conditions such as cancer, immune system disorders, chronic diseases, infectious diseases, and mental health.

Cradle is a protein engineering platform that uses machine learning to design improved protein sequences. It allows users to import assay data, generate new sequences, test them in the lab, and import the results to improve the model. Cradle can be used to optimize multiple properties of a protein simultaneously, and it has been used by leading biotech teams to accelerate new and ongoing projects.

PubCompare is a powerful AI-powered tool that helps scientists search, compare, and evaluate experimental protocols. With over 40 million protocols in its database, PubCompare is the largest repository of trusted experimental protocols. PubCompare's AI-powered search features allow users to find similar protocols, highlight critical steps, and evaluate the reproducibility of protocols based on in-protocol citations. PubCompare is available from any computer and requires no download.

Insitro is a drug discovery and development company that uses machine learning and data to identify and develop new medicines. The company's platform integrates in vitro cellular data produced in its labs with human clinical data to help redefine disease. Insitro's pipeline includes wholly-owned and partnered therapeutic programs in metabolism, oncology, and neuroscience.

Deep Genomics is a company that uses artificial intelligence (AI) to develop RNA therapies for genetic diseases. The company's AI platform is designed to identify novel targets and evaluate thousands of possibilities to identify the best therapeutic candidates. Deep Genomics is currently developing BigRNA+, which will expand the number of mechanisms and genetic variants the company can pursue.

BenevolentAI is a leader in applying advanced AI to accelerate biopharma drug discovery blending science and technology with a focus on finding solutions for complex diseases. We empower both biopharmaceutical companies and our internal scientists to harness the full potential of data and AI to accelerate the next generation of scientific advances. We have built our AI-enabled drug discovery engine to drive a revolution in drug discovery. The Benevolent Platform™ unlocks the power of a vast biomedical data landscape to provide a multidimensional representation of human biology across all diseases. We believe this approach will improve the probability of clinical success, and help us deliver life-changing treatments to patients – because it matters.

XtalPi is a world-leading technology company driven by artificial intelligence (AI) and robotics to innovate in the fields of life sciences and new materials. Founded in 2015 at the Massachusetts Institute of Technology (MIT), the company is committed to realizing digital and intelligent innovation in the fields of life sciences and new materials. Based on cutting-edge technologies and capabilities such as quantum physics, artificial intelligence, cloud computing, and large-scale experimental robot clusters, the company provides innovative technologies, services, and products for global industries such as biomedicine, chemicals, new energy, and new materials.

Iambic Therapeutics is a cutting-edge AI-driven drug discovery platform that tackles the most challenging design problems in drug discovery, addressing unmet patient need. Its physics-based AI algorithms drive a high-throughput experimental platform, converting new molecular designs to new biological insights each week. Iambic's platform optimizes target product profiles, exploring multiple profiles in parallel to ensure that molecules are designed to solve the right problems in disease biology. It also optimizes drug candidates, deeply exploring chemical space to reveal novel mechanisms of action and deliver diverse high-quality leads.

Tempus is an AI-enabled precision medicine company that brings the power of data and artificial intelligence to healthcare. With the power of AI, Tempus accelerates the discovery of novel targets, predicts the effectiveness of treatments, identifies potentially life-saving clinical trials, and diagnoses multiple diseases earlier. Tempus' innovative technology includes ONE, an AI-enabled clinical assistant; NEXT, which identifies and closes gaps in care; LENS, which finds, accesses, and analyzes multimodal real-world data; and ALGOS, algorithmic models connected to Tempus' assays to provide additional insight.

Bionl is a no-code bioinformatics platform designed to streamline biomedical research for researchers and scientists. It offers a full workspace with features such as bioinformatics pipelines customization, GenAI for data analysis, AI-powered literature search, PDF analysis, and access to public datasets. Bionl aims to automate cloud, file system, data, and workflow management for efficient and precise analyses. The platform caters to Pharma and Biotech companies, academic researchers, and bioinformatics CROs, providing powerful tools for genetic analysis and speeding up research processes.

Genie TechBio is the world's first AI bioinformatician, offering an LLM-powered omics analysis software that operates entirely in natural language, eliminating the need for coding. Researchers can effortlessly analyze extensive datasets by engaging in a conversation with Genie, receiving recommendations for analysis pipelines, and obtaining results. The tool aims to accelerate biomedical research and empower scientists with newfound data analysis capabilities.

HoloEye.AI is a transformative AI biological intelligence company that leverages cutting-edge artificial intelligence technology to revolutionize the field of biological research. The platform offers advanced AI solutions for analyzing complex biological data, enabling researchers to gain deeper insights and accelerate scientific discoveries.

Mapmygenome is an AI-powered platform that offers DNA testing products for health, fitness, and beauty. It provides personalized insights based on genetic analysis to help individuals make informed decisions about their health, wellness, and lifestyle choices. With over 23 years of genomics experience and the latest sequencing technology, Mapmygenome aims to empower users to take proactive steps towards improving their overall well-being.

DrugCard is an AI-enabled Data Intelligence platform designed to streamline drug safety routines, particularly in pharmacovigilance. It offers solutions for local literature screening, catering to CROs, MAHs, and freelancers in the pharmaceutical industry. The platform supports multiple languages, covers various medical journals, and saves significant time compared to manual approaches. DrugCard aims to enhance pharmacovigilance processes by leveraging AI, automation, and traceability to meet regulatory requirements and improve screening results.

Beacon Biosignals provides an EEG neurobiomarker platform that is designed to accelerate clinical trials and enable new treatments for patients with neurological and psychiatric diseases. Their platform is powered by machine learning and a world-class clinico-EEG database, which allows them to analyze existing EEG data for insights into mechanisms, PK/PD, and patient stratification. This information can be used to guide further development efforts, optimize clinical trials, and enhance understanding of treatment efficacy.

AiCure provides a patient-centric eClinical trial management platform that enhances drug development through improved medication adherence rates, more powerful analysis and prediction of treatment response using digital biomarkers, and reduced clinical tech burden. AiCure's solutions support traditional, decentralized, or hybrid trials and offer flexibility to meet the needs of various research designs.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques. The company's proprietary AI platform is used to identify, re-innovate, and develop potential new therapies. BioXcel Therapeutics has a pipeline of product candidates in various stages of development, including BXCL501 for agitation in dementia, BXCL701 for cocaine use disorder, and BXCL801 for acute suicidal ideation and behavior in patients with major depressive disorder.

Intelligencia AI is a leading provider of AI-powered solutions for the pharmaceutical industry. Our suite of solutions helps de-risk and enhance clinical development and decision-making. We use a combination of data, AI, and machine learning to provide insights into the probability of success for drugs across multiple therapeutic areas. Our solutions are used by many of the top global pharmaceutical companies to improve their R&D productivity and make more informed decisions.

Cambrian Copilot is an AI tool designed for researchers and engineers to stay updated with the latest machine learning research. It provides access to over 240,000 ML papers, helps in understanding complex details, and automates literature reviews. The tool simplifies the process of discovering and accessing the most recent research developments in the field of machine learning.

NexusGPT is an AI tool that allows users to build and deploy custom AI agents for various workflows without the need for coding. It offers enterprise-grade AI solutions that can be integrated into any app, providing autonomous agents that can complete complex tasks, automate processes, and enhance productivity. With features like connecting to external plugins, enterprise-grade security, and deployment on existing apps, NexusGPT empowers users to create powerful AI agents effortlessly.

Emotion Logic Ltd is an AI tool that specializes in genuine emotion detection from voice data. The technology provides valuable insights across various sectors, including fraud investigations, healthcare, education, and customer service. Emotion Logic's advanced voice analysis capabilities help in deciphering unspoken emotions accurately, enhancing user experiences, and gaining valuable insights for decision-making processes.

functime is a time-series machine learning tool designed for scalability. It offers a comprehensive set of functions and features to facilitate time-series forecasting and analysis. With functime, users can easily install the tool, access documentation, tutorials, and API references. The tool provides scoring, ranking, and plotting functions for evaluating forecasts, making it a valuable resource for forecast analysts. Additionally, functime serves as an AI copilot, assisting users in analyzing trends, seasonality, and causal factors in their forecasts.

Kolank is an AI tool that offers a unified API with features such as load balancing, fallbacks, cost and performance metrics. Users can access models for generating text, images, and videos through simple API calls. The platform supports multiple programming languages like Python, JavaScript, and Curl, making it easy for developers to integrate AI capabilities into their applications.

Promptmakr is a platform that facilitates the buying and selling of AI prompts. It serves as a marketplace where users can find and purchase prompts for various AI applications. The platform aims to streamline the process of acquiring prompts, making it easier for developers and AI enthusiasts to access high-quality content to enhance their projects.